Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HIV Diagnostics and Vaccines: It Takes Two to Tango.
Colón W, Oriol-Mathieu V, Hural J, Hattingh L, Adungo F, Lagatie O, Lavreys L, Allen M, Anzala O, Espy N, Fransen K, Garcia PJ, Maciel M Jr, Murtagh M, Peel SA, Peeling RW, Tan LLJ, Warren M, Pau MG, D'Souza PM. Colón W, et al. Among authors: anzala o. J Infect Dis. 2024 Jun 14;229(6):1919-1925. doi: 10.1093/infdis/jiae113. J Infect Dis. 2024. PMID: 38451247 Review.
Early antiretroviral therapy and its impact on natural killer cell dynamics in HIV-1 infected men who have sex with men: a cross-sectional pilot study evaluating the impact of early ART initiation on NK cell perturbation in HIV infection.
Akiso M, Muema D, Langat R, Naidoo KK, Oino G, Mutua G, Thobakgale C, Ochiel D, Chinyenze K, Anzala O, Mureithi MW. Akiso M, et al. Among authors: anzala o. Microbiol Spectr. 2024 Apr 2;12(4):e0357023. doi: 10.1128/spectrum.03570-23. Epub 2024 Feb 16. Microbiol Spectr. 2024. PMID: 38364104 Free PMC article.
Temporal trends and transmission dynamics of pre-treatment HIV-1 drug resistance within and between risk groups in Kenya, 1986-2020.
Nduva GM, Otieno F, Kimani J, Sein Y, Arimide DA, Mckinnon LR, Cholette F, Lawrence MK, Majiwa M, Masika M, Mutua G, Anzala O, Graham SM, Gelmon L, Price MA, Smith AD, Bailey RC, Medstrand P, Sanders EJ, Esbjörnsson J, Hassan AS. Nduva GM, et al. Among authors: anzala o. J Antimicrob Chemother. 2024 Feb 1;79(2):287-296. doi: 10.1093/jac/dkad375. J Antimicrob Chemother. 2024. PMID: 38091580 Free PMC article.
Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda.
Man-Lik Choi E, Abu-Baker Mustapher G, Omosa-Manyonyi G, Foster J, Anywaine Z, Musila Mutua M, Ayieko P, Vudriko T, Ann Mwangi I, Njie Y, Ayoub K, Mundia Muriuki M, Kasonia K, Edward Connor N, Florence N, Manno D, Katwere M, McLean C, Gaddah A, Luhn K, Lowe B, Greenwood B, Robinson C, Anzala O, Kaleebu P, Watson-Jones D; EBL2010 Study Team. Man-Lik Choi E, et al. Among authors: anzala o. Vaccine. 2023 Dec 7;41(50):7573-7580. doi: 10.1016/j.vaccine.2023.10.055. Epub 2023 Nov 18. Vaccine. 2023. PMID: 37981473 Free article. Clinical Trial.
138 results